Reported Saturday, Pfizer Presents Phase 2 25vPnC Infant Data At IDWeek 2026: Robust Responses To All 25 Serotypes, Including Five New, Safety Comparable To PREVNAR 20, No Related Serious Adverse Events

Loading news article.

Reported Saturday, Pfizer Presents Phase 2 25vPnC Infant Data At IDWeek 2026: Robust Responses To All 25 Serotypes, Including Five New, Safety Comparable To PREVNAR 20, No Related Serious Adverse Events | WAPE

Reported Saturday, Pfizer Presents Phase 2 25vPnC Infant Data At IDWeek 2026: Robust Responses To All 25 Serotypes, Including Five New, Safety Comparable To PREVNAR 20, No Related Serious Adverse Events

Article summary

Related companies

Comments —